De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Anagenics Beheer

Beheer criteriumcontroles 1/4

De CEO Anagenics' is Karen Matthews, benoemd in Jan2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.14% van de aandelen van het bedrijf, ter waarde A$ 5.00K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.5 jaar en 2.5 jaar.

Belangrijke informatie

Karen Matthews

Algemeen directeur

AU$19.2k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	1.5yrs
Gemiddelde ambtstermijn bestuur	2.5yrs

Recente managementupdates

Recent updates

How Much is Cellmid's (ASX:CDY) CEO Getting Paid?

Dec 17

CEO

Karen Matthews

less than a year

Tenure

AU$19,168

Compensatie

Ms. Karen Matthews serves as Chief Executive Officer and Director at Anagenics Limited from 2024 and serves as its Non-Executive Director from February 14, 2023. She brings dynamic experience from the Beau...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Karen Matthews	CEO & Director	less than a year	AU$19.17k	0.14% A$ 5.0k
Matthew Dudek	Chief Financial & Governance Officer and Company Secretary	1.5yrs	AU$282.67k	geen gegevens
Scott Greasley	Executive Director	no data	AU$1.15m	0.52% A$ 19.1k
Dominic Burg	Chief Operating Officer	4.3yrs	geen gegevens	geen gegevens
Graham Robertson	Head of Research & Development	no data	geen gegevens	geen gegevens

1.5yrs

Gemiddelde duur

Ervaren management: Het managementteam van AN1 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Karen Matthews	CEO & Director	1.7yrs	AU$19.17k	0.14% A$ 5.0k
Scott Greasley	Executive Director	2.3yrs	AU$1.15m	0.52% A$ 19.1k
Alexander Beard	Non-Executive Chairman	2.7yrs	AU$35.00k	0.94% A$ 34.7k
Phillip Christopher	Non-Executive Director	2.9yrs	AU$26.67k	0.41% A$ 15.0k

2.5yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van AN1 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.5 jaar), wat duidt op een nieuw bestuur.

Anagenics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Anagenics Limited, Annual General Meeting, Nov 27, 2023

Anagenics Limited Appoints Karen Matthews as Non-Executive Director

Anagenics Approves the Election of Mr. Alexander Beard as A Director

No independent directors

Anagenics Limited, Annual General Meeting, Nov 29, 2022

Anagenics Limited Announces Resignation of Dennis Eck as Director

Recent updates

Matthew Perry, Sarah Jane Perry, and entities they control agreed to acquire Face Medigroup Retail Pty Ltd from Anagenics Limited (ASX:AN1).

New major risk - Financial position

Anagenics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.32068 million.

Anagenics Limited, Annual General Meeting, Nov 27, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.017 loss in FY 2022)

Anagenics Limited (ASX:AN1) agreed to acquire Face MediGroup for AUD 1.3 million.

New minor risk - Financial data availability

Anagenics Limited Appoints Karen Matthews as Non-Executive Director

First half 2023 earnings released: AU$0.002 loss per share (vs AU$0.009 loss in 1H 2022)

Anagenics Limited (ASX:AN1) acquired Uspa Global Pty. Ltd. from BWX Limited (ASX:BWX).

Anagenics Approves the Election of Mr. Alexander Beard as A Director

No independent directors

Anagenics Limited, Annual General Meeting, Nov 29, 2022

Anagenics Limited Announces Resignation of Dennis Eck as Director

Full year 2022 earnings released: AU$0.017 loss per share (vs AU$0.027 loss in FY 2021)

Anagenics Limited Appoints Scott Mitchell Greasley as Director

Anagenics Limited Appoints Matthew Dudek as Acting Chief Executive Officer, Effective 28 February 2022

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Anagenics Limited Appoints Mr. Alexander (Sandy) Beard as Director

Full year 2021 earnings released: AU$0.027 loss per share (vs AU$0.045 loss in FY 2020)

Full year 2021 earnings released: AU$0.027 loss per share (vs AU$0.05 loss in FY 2020)

An unknown buyer signed a binding agreement to acquired Lyramid Limited from Cellmid Limited (ASX:CDY) for AUD 0.5 million

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.016 loss in 1H 2020)

Cellmid Limited Publishes Data on Novel Proprietary FGF5 Aptamer

Cellmid Limited Receives the First Order from Ourui Health Management Limited

Cellmid Limited Announces Executive Changes

How Much is Cellmid's (ASX:CDY) CEO Getting Paid?

Cellmid Limited, Advangen Limited and Advangen Inc. Signs 10 Year Chinese Distribution Agreement with Ourui Health Management Limited

Cellmid Limited Appoints Sarah Eck-Thompson as Director

Full year earnings released - AU$0.05 loss per share

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur